Zealand Pharma reports ZP9830 well tolerated in Phase 1 multiple-dose trial

Bitget2026/10/19 05:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zealand Pharma announced positive Phase 1 multiple-dose results for ZP9830, its Kv1.3 ion channel blocker, on October 19, 2026.
The trial enrolled 32 healthy participants, with four weeks of treatment and safety follow-up through day 41.
All treatment-emergent adverse events with ZP9830 were mild and non-serious; no dose-limiting safety findings emerged.
Pharmacokinetic results support longer-duration studies; a Phase 1b trial with efficacy endpoints in plaque psoriasis is underway.
A Phase 2 trial in an additional autoimmune disease is planned to start in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190100PRIMZONEFULLFEED1001278536) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zealand Pharma reports ZP9830 well tolerated in Phase 1 multiple-dose trial

You may also like

Crypto prices